fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Nadroparin calcium

Form:

7 of 7 products shown

All strengths: Limited Use, Reason for Use code 186, 187, 188, 189 required; same patient cost rules

Shared coverage and patient cost rules
StatusLimited Use, Reason for Use code 186, 187, 188, 189 required
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]

Fraxiparine · PIN 09853936 · 9500 IU/mL · pre-filled syringe-0.3mL Pk

Limited Use, Reason for Use code 186, 187, 188, 189 requiredOntario PIN; no Health Canada record under this code
Write on scriptone applicable Reason for Use code, 186 or 187 or 188 or 189 (criteria below)

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check Health Canada brand search

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Ontario Limited Use criteria, code 186, 187, 188, 189
Reason for Use code 186 For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks; Coverage limit: LU Authorization Period: 1 year Reason for Use code 187 For DVT in pregnant or lactating females; Coverage limit: LU Authorization Period: 1 year Reason for Use code 188 For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated; Coverage limit: LU Authorization Period: 1 year Reason for Use code 189 For DVT in patients who have failed treatment with warfarin. Coverage limit: LU Authorization Period: 1 year Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Nadroparin Brand(s): Fraxiparine DOSAGE FORM/ STRENGTH: Check formulary or e-formulary for funded products For the post-operative prophylaxis of venous thromboembolism following abdominal or pelvic surgery for cancer in patients who do not have a history of or risk factors for heparin-induced thrombocytopenia. Standard Approval Duration: Maximum of 30 days 30 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 30, record 10, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 28, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days | (ontario.ca, Updated October 05, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated October 05, 2026 ↗)
No interchangeable product listed in the Ontario extract
Fraxiparine · DIN 09853936 Manufacturer: Aspen Pharma Trading Limited; listing date 1999-04-15 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Re-check Health Canada status and shortages (live)

Fraxiparine: Formulary list price $5.42 per unit (the source does not state the unit; exact figure $5.4150). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09853936)

Source record
DIN 09853936: Fraxiparine Raw flags: sec12=Y, sec3=Y Item: 201200050; group id 258; item number 0499; lccId 00047; manufacturer id ASN Source form: Pref Syr-0.3mL Pk; strength: 9500IU/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $5.4150; ministry $5.4150 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=09853936 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=09853936
Shortage record checked October 6, 2026

Fraxiparine · PIN 09853944 · 9500 IU/mL · pre-filled syringe-0.4mL Pk

Limited Use, Reason for Use code 186, 187, 188, 189 requiredOntario PIN; no Health Canada record under this code
Write on scriptone applicable Reason for Use code, 186 or 187 or 188 or 189 (criteria below)

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check Health Canada brand search

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Ontario Limited Use criteria, code 186, 187, 188, 189
Reason for Use code 186 For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks; Coverage limit: LU Authorization Period: 1 year Reason for Use code 187 For DVT in pregnant or lactating females; Coverage limit: LU Authorization Period: 1 year Reason for Use code 188 For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated; Coverage limit: LU Authorization Period: 1 year Reason for Use code 189 For DVT in patients who have failed treatment with warfarin. Coverage limit: LU Authorization Period: 1 year Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Nadroparin Brand(s): Fraxiparine DOSAGE FORM/ STRENGTH: Check formulary or e-formulary for funded products For the post-operative prophylaxis of venous thromboembolism following abdominal or pelvic surgery for cancer in patients who do not have a history of or risk factors for heparin-induced thrombocytopenia. Standard Approval Duration: Maximum of 30 days 30 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 30, record 10, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 28, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days | (ontario.ca, Updated October 05, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated October 05, 2026 ↗)
No interchangeable product listed in the Ontario extract
Fraxiparine · DIN 09853944 Manufacturer: Aspen Pharma Trading Limited; listing date 1999-04-15 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Re-check Health Canada status and shortages (live)

Fraxiparine: Formulary list price $6.84 per unit (the source does not state the unit; exact figure $6.8400). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09853944)

Source record
DIN 09853944: Fraxiparine Raw flags: sec12=Y, sec3=Y Item: 201200051; group id 258; item number 0500; lccId 00047; manufacturer id ASN Source form: Pref Syr-0.4mL Pk; strength: 9500IU/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $6.8400; ministry $6.8400 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=09853944 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=09853944
Shortage record checked October 6, 2026

Fraxiparine · PIN 09853952 · 9500 IU/mL · pre-filled syringe-0.6mL Pk

Limited Use, Reason for Use code 186, 187, 188, 189 requiredOntario PIN; no Health Canada record under this code
Write on scriptone applicable Reason for Use code, 186 or 187 or 188 or 189 (criteria below)

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check Health Canada brand search

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Ontario Limited Use criteria, code 186, 187, 188, 189
Reason for Use code 186 For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks; Coverage limit: LU Authorization Period: 1 year Reason for Use code 187 For DVT in pregnant or lactating females; Coverage limit: LU Authorization Period: 1 year Reason for Use code 188 For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated; Coverage limit: LU Authorization Period: 1 year Reason for Use code 189 For DVT in patients who have failed treatment with warfarin. Coverage limit: LU Authorization Period: 1 year Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Nadroparin Brand(s): Fraxiparine DOSAGE FORM/ STRENGTH: Check formulary or e-formulary for funded products For the post-operative prophylaxis of venous thromboembolism following abdominal or pelvic surgery for cancer in patients who do not have a history of or risk factors for heparin-induced thrombocytopenia. Standard Approval Duration: Maximum of 30 days 30 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 30, record 10, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 28, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days | (ontario.ca, Updated October 05, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated October 05, 2026 ↗)
No interchangeable product listed in the Ontario extract
Fraxiparine · DIN 09853952 Manufacturer: Aspen Pharma Trading Limited; listing date 1999-04-15 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Re-check Health Canada status and shortages (live)

Fraxiparine: Formulary list price $9.06 per unit (the source does not state the unit; exact figure $9.0580). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09853952)

Source record
DIN 09853952: Fraxiparine Raw flags: sec12=Y, sec3=Y Item: 201200052; group id 258; item number 0501; lccId 00047; manufacturer id ASN Source form: Pref Syr-0.6mL Pk; strength: 9500IU/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $9.0580; ministry $9.0580 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=09853952 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=09853952
Shortage record checked October 6, 2026

Fraxiparine · PIN 09853987 · 9500 IU/mL · pre-filled syringe-1.0mL Pk

Limited Use, Reason for Use code 186, 187, 188, 189 requiredOntario PIN; no Health Canada record under this code
Write on scriptone applicable Reason for Use code, 186 or 187 or 188 or 189 (criteria below)

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check Health Canada brand search

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Ontario Limited Use criteria, code 186, 187, 188, 189
Reason for Use code 186 For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks; Coverage limit: LU Authorization Period: 1 year Reason for Use code 187 For DVT in pregnant or lactating females; Coverage limit: LU Authorization Period: 1 year Reason for Use code 188 For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated; Coverage limit: LU Authorization Period: 1 year Reason for Use code 189 For DVT in patients who have failed treatment with warfarin. Coverage limit: LU Authorization Period: 1 year Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Nadroparin Brand(s): Fraxiparine DOSAGE FORM/ STRENGTH: Check formulary or e-formulary for funded products For the post-operative prophylaxis of venous thromboembolism following abdominal or pelvic surgery for cancer in patients who do not have a history of or risk factors for heparin-induced thrombocytopenia. Standard Approval Duration: Maximum of 30 days 30 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 30, record 10, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 28, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days | (ontario.ca, Updated October 05, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated October 05, 2026 ↗)
No interchangeable product listed in the Ontario extract
Fraxiparine · DIN 09853987 Manufacturer: Aspen Pharma Trading Limited; listing date 1999-04-15 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Re-check Health Canada status and shortages (live)

Fraxiparine: Formulary list price $9.06 per unit (the source does not state the unit; exact figure $9.0580). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09853987)

Source record
DIN 09853987: Fraxiparine Raw flags: sec12=Y, sec3=Y Item: 201200054; group id 258; item number 0504; lccId 00047; manufacturer id ASN Source form: Pref Syr-1.0mL Pk; strength: 9500IU/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $9.0580; ministry $9.0580 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=09853987 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=09853987
Shortage record checked October 6, 2026

Fraxiparine Forte · DIN 02240114 · 19000 IU/mL · pre-filled syringe-0.6mL Pk

Limited Use, Reason for Use code 186, 187, 188, 189 requiredApproved · checked October 5, 2026
Write on scriptone applicable Reason for Use code, 186 or 187 or 188 or 189 (criteria below)

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Ontario Limited Use criteria, code 186, 187, 188, 189
Reason for Use code 186 For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks; Coverage limit: LU Authorization Period: 1 year Reason for Use code 187 For DVT in pregnant or lactating females; Coverage limit: LU Authorization Period: 1 year Reason for Use code 188 For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated; Coverage limit: LU Authorization Period: 1 year Reason for Use code 189 For DVT in patients who have failed treatment with warfarin. Coverage limit: LU Authorization Period: 1 year Exceptional Access criteria on record are for Brand(s): Fraxiparine; DOSAGE FORM/ STRENGTH: Check formulary or e-formulary for funded products — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Nadroparin Brand(s): Fraxiparine DOSAGE FORM/ STRENGTH: Check formulary or e-formulary for funded products For the post-operative prophylaxis of venous thromboembolism following abdominal or pelvic surgery for cancer in patients who do not have a history of or risk factors for heparin-induced thrombocytopenia. Standard Approval Duration: Maximum of 30 days 30 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 30, record 10, corpus 2025-01-01; name match only, not an eligibility decision
No interchangeable product listed in the Ontario extract
Fraxiparine Forte · DIN 02240114 Manufacturer: Aspen Pharma Trading Limited; listing date 2000-01-17 Health Canada: Approved since 2026-05-21 · brand FRAXIPARINE FORTE · ATC B01AB06 NADROPARIN · form Solution · route Intravenous, Subcutaneous · ingredients NADROPARIN CALCIUM 19000 UNIT/ML · company Aspen pharmacare canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Fraxiparine Forte: Formulary list price $18.12 per unit (the source does not state the unit; exact figure $18.1170). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02240114)

Source record
DIN 02240114: Fraxiparine Forte Raw flags: sec12=Y, sec3=Y Item: 201200059; group id 258; item number 0502; lccId 00047; manufacturer id ASN Source form: Pref Syr-0.6mL Pk; strength: 19000IU/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $18.1170; ministry $18.1170 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02240114 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63628
Shortage status: active shortage (reported October 29, 2020, last updated October 30, 2020) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02240114
Shortage record checked October 6, 2026
Health Canada lists this DIN as Approved since May 21, 2026 — choose a marketed DIN from the same-category list.

Fraxiparine Forte · PIN 09854100 · 19000 IU/mL · pre-filled syringe-0.8mL Pk

Limited Use, Reason for Use code 186, 187, 188, 189 requiredOntario PIN; no Health Canada record under this code
Write on scriptone applicable Reason for Use code, 186 or 187 or 188 or 189 (criteria below)

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check Health Canada brand search

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Ontario Limited Use criteria, code 186, 187, 188, 189
Reason for Use code 186 For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks; Coverage limit: LU Authorization Period: 1 year Reason for Use code 187 For DVT in pregnant or lactating females; Coverage limit: LU Authorization Period: 1 year Reason for Use code 188 For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated; Coverage limit: LU Authorization Period: 1 year Reason for Use code 189 For DVT in patients who have failed treatment with warfarin. Coverage limit: LU Authorization Period: 1 year Exceptional Access criteria on record are for Brand(s): Fraxiparine; DOSAGE FORM/ STRENGTH: Check formulary or e-formulary for funded products — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Nadroparin Brand(s): Fraxiparine DOSAGE FORM/ STRENGTH: Check formulary or e-formulary for funded products For the post-operative prophylaxis of venous thromboembolism following abdominal or pelvic surgery for cancer in patients who do not have a history of or risk factors for heparin-induced thrombocytopenia. Standard Approval Duration: Maximum of 30 days 30 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 30, record 10, corpus 2025-01-01; name match only, not an eligibility decision
No interchangeable product listed in the Ontario extract
Fraxiparine Forte · DIN 09854100 Manufacturer: Aspen Pharma Trading Limited; listing date 2000-01-17 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Re-check Health Canada status and shortages (live)

Fraxiparine Forte: Formulary list price $18.12 per unit (the source does not state the unit; exact figure $18.1170). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09854100)

Source record
DIN 09854100: Fraxiparine Forte Raw flags: sec12=Y, sec3=Y Item: 201200060; group id 258; item number 0503; lccId 00047; manufacturer id ASN Source form: Pref Syr-0.8mL Pk; strength: 19000IU/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $18.1170; ministry $18.1170 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=09854100 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=09854100
Shortage record checked October 6, 2026

Fraxiparine Forte · PIN 09854118 · 19000 IU/mL · pre-filled syringe-1.0mL Pk

Limited Use, Reason for Use code 186, 187, 188, 189 requiredOntario PIN; no Health Canada record under this code
Write on scriptone applicable Reason for Use code, 186 or 187 or 188 or 189 (criteria below)

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check Health Canada brand search

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Ontario Limited Use criteria, code 186, 187, 188, 189
Reason for Use code 186 For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks; Coverage limit: LU Authorization Period: 1 year Reason for Use code 187 For DVT in pregnant or lactating females; Coverage limit: LU Authorization Period: 1 year Reason for Use code 188 For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated; Coverage limit: LU Authorization Period: 1 year Reason for Use code 189 For DVT in patients who have failed treatment with warfarin. Coverage limit: LU Authorization Period: 1 year Exceptional Access criteria on record are for Brand(s): Fraxiparine; DOSAGE FORM/ STRENGTH: Check formulary or e-formulary for funded products — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Nadroparin Brand(s): Fraxiparine DOSAGE FORM/ STRENGTH: Check formulary or e-formulary for funded products For the post-operative prophylaxis of venous thromboembolism following abdominal or pelvic surgery for cancer in patients who do not have a history of or risk factors for heparin-induced thrombocytopenia. Standard Approval Duration: Maximum of 30 days 30 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 30, record 10, corpus 2025-01-01; name match only, not an eligibility decision
No interchangeable product listed in the Ontario extract
Fraxiparine Forte · DIN 09854118 Manufacturer: Aspen Pharma Trading Limited; listing date 2000-01-17 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Re-check Health Canada status and shortages (live)

Fraxiparine Forte: Formulary list price $18.12 per unit (the source does not state the unit; exact figure $18.1170). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09854118)

Source record
DIN 09854118: Fraxiparine Forte Raw flags: sec12=Y, sec3=Y Item: 201200061; group id 258; item number 0505; lccId 00047; manufacturer id ASN Source form: Pref Syr-1.0mL Pk; strength: 19000IU/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $18.1170; ministry $18.1170 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=09854118 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=09854118
Shortage record checked October 6, 2026

Other products in the same Health Canada class (B01A, B01AB): coverage varies; not interchangeable

  • Enoxaparin (Noromby): general benefit
  • Dalteparin (Fragmin): limited Use 186, 187, 188, 189
  • Tinzaparin (Innohep): limited Use 186, 187, 188, 189, 323
  • Apixaban (Eliquis): general benefit
  • Dabigatran etexilate (Pradaxa): general benefit, not a benefit
  • Edoxaban (Lixiana): general benefit

5 more in the class list below

Other drugs in the same formulary class (20:12 Coagulants and Anti-Coagulants) and how they are covered

Matched class: 20:12 Coagulants and Anti-Coagulants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: APIXABAN, ENOXAPARIN, RIVAROXABAN Some products covered without a code (check the product listing): DABIGATRAN ETEXILATE, EDOXABAN, WARFARIN 20:12 Coagulants and Anti-Coagulants

ENOXAPARIN

· 37 products · General benefit · strengths: 20mg/0.2mL, 30mg/0.3mL, 40mg/0.4mL, 60mg/0.6mL, 80mg/0.8mL, 120mg/0.8mL, 100mg/mL, 150mg/mL, 300mg/3mL · Inj Sol-0.2mL Pref Syr (Preservative-Free), Inj Sol-0.3mL Pref Syr (Preservative-Free), Inj Sol-0.4mL Pref Syr (Preservative-Free), Inj Sol-0.6mL Pref Syr (Preservative-Free), Inj Sol-0.8mL Pref Syr (Preservative-Free), Inj Sol-1mL Pref Syr (Preservative-Free), Inj Sol-3mL Vial Pk (With Preservative)

DALTEPARIN SODIUM

· 10 products · Limited Use, codes 186, 187, 188, 189 · strengths: 3500IU/0.28mL, 7500IU/0.3mL, 2500IU/0.2mL, 5000IU/0.2mL, 10000IU/0.4mL, 12500IU/0.5mL, 15000IU/0.6mL, 18000IU/0.72mL, 16500IU/0.66mL, 25000IU/mL · Inj Pref Syr, Inj Pref Syr-0.66mL Pk, Multidose 3.8mL Pk

TINZAPARIN SODIUM

· 11 products · Limited Use, codes 186, 187, 188, 189, 323 · strengths: 2500IU/0.25mL, 8000IU/0.4mL, 12000IU/0.6mL, 16000IU/0.8mL, 3500IU/0.35mL, 4500IU/0.45mL, 10000IU/0.5mL, 14000IU/0.7mL, 18000IU/0.9mL, 10000IU/mL, 20000IU/mL · Inj Pref Syr, Inj-2mL Pk

APIXABAN

· 38 products · General benefit · strengths: 2.5mg, 5mg · Tab

DABIGATRAN ETEXILATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit (2), General benefit (4) · strengths: 75mg, 110mg, 150mg · Cap

RIVAROXABAN

· 50 products · General benefit · strengths: 2.5mg, 10mg, 15mg, 20mg · Tab

WARFARIN

· 23 products · Listed, not a benefit (8), General benefit (14), Off-Formulary Interchangeable, not an ODB benefit (1) · strengths: 1mg, 2mg, 2.5mg, 3mg, 4mg, 5mg, 6mg, 10mg · Tab

FONDAPARINUX SODIUM

· 4 products · Limited Use, codes 378 (2), Off-Formulary Interchangeable, not an ODB benefit (2) · strengths: 2.5mg/0.5mL, 7.5mg/0.6mL · Inj Sol-Pref Syr 0.5mL Pk (Preservative Free), Inj Sol-Pref Syr 0.6mL Pk (Preservative Free)

TICAGRELOR

· 10 products · Off-Formulary Interchangeable, not an ODB benefit (5), Limited Use, codes 441 (5) · strengths: 60mg, 90mg · Tab

EPTIFIBATIDE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.75mg/mL, 2mg/mL · 100mL Vial Pk, 10mL Vial Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 20:12 20:12:04 Direct Factor Xa Inhibitors

EDOXABAN

· 11 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (3), General benefit (8) · strengths: 15mg, 30mg, 60mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 20:12:04 20:12:16 Hemostatics

TRANEXAMIC ACID

· 5 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 500mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 20:12:16
Full class listing Related classes: 20:04 Antianemia Drugs, 20:16 Hematopoietic Agents, 20:24 Hemorrheologic Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
Product monograph unavailable: no marketed product found

Availability

Fraxiparine Forte · DIN 02240114 Shortage status: active shortage (reported 2020-10-29, last updated 2020-10-30) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02240114

Check this DIN again
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Prepare an Exceptional Access request

SADIE has its own form for many drugs; this checklist prepares the answers; the ministry decides. Open SADIE

Use this text in SADIE’s free-text fields or read from it on a Telephone Request Service call. Review marks do not indicate eligibility. Evidence stays in this page until you copy it; nothing entered here is sent or saved. Do not enter patient identifiers.

EAP Telephone Request Service: The TRS can be accessed by calling toll-free at 1-866-811-9893 or 416-327-8109 (Toronto area) between 8:30 a.m. and 5:00 p.m. Monday through Friday (except holidays) and selecting the TRS option. Source; updated September 15, 2026

EAP fax: In Ontario: 1-866-811-9908 or 416-327-7526 (Toronto area). Outside Ontario: 1-833-905-4260. Source; updated September 15, 2026

Posted turnaround and Telephone Request Service scope
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 28, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days |
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
Source; updated October 05, 2026

Nadroparin (Fraxiparine)

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Prepare answers: See the ministry wording below; no separate indication heading is held.

Ministry criteria corpus 2025-01-01; page 30

Nadroparin Brand(s): Fraxiparine DOSAGE FORM/ STRENGTH: Check formulary or e-formulary for funded products
For the post-operative prophylaxis of venous thromboembolism following abdominal or pelvic surgery for cancer in patients who do not have a history of or risk factors for heparin-induced thrombocytopenia. Standard Approval Duration: Maximum of 30 days
30

Prepared from the ministry's published criteria; eligibility is decided by the Exceptional Access Program.